Axelyf, Inc.
Axelyf is an R&D-focused biotechnology company founded in Iceland (with a U.S. parent corporation) that develops lipid nanoparticle (LNP) delivery technologies and complementary chemistries to enable safer, more potent RNA medicines. The team combines nanotechnology formulation experience, a proprietary molecular lipid library, AI-driven modeling for LNP performance, and prodrug research to advance preclinical mRNA and gene-editing delivery programs and partner with external developers.
Industries
N/A
Nr. of Employees
small (1-50)
Axelyf, Inc.
Founded in Hafnarfjörður, Iceland; Delaware C-corporation (Boston, MA), USA
Products
Proprietary lipid library for LNP formulation
An integrated molecular library of novel lipids and formulation variants developed to identify potent delivery compounds for mRNA and other biomolecular cargos.
AI model for nanoparticle performance prediction
A machine-learning model that predicts LNP potency and compares candidates on a common scale across heterogeneous datasets to guide virtual screening and candidate selection.
Prodrug candidate for inflammatory disease (preclinical)
A proprietary prodrug candidate developed from a natural-product scaffold with demonstrated efficacy in a preclinical arthritis model.
Proprietary lipid library for LNP formulation
An integrated molecular library of novel lipids and formulation variants developed to identify potent delivery compounds for mRNA and other biomolecular cargos.
AI model for nanoparticle performance prediction
A machine-learning model that predicts LNP potency and compares candidates on a common scale across heterogeneous datasets to guide virtual screening and candidate selection.
Prodrug candidate for inflammatory disease (preclinical)
A proprietary prodrug candidate developed from a natural-product scaffold with demonstrated efficacy in a preclinical arthritis model.
Services
Collaborative discovery and development agreements to apply lipid library and formulation expertise to partner programs; multi-year collaborations for chemistry and bio-analytical support.
Collaborative discovery and development agreements to apply lipid library and formulation expertise to partner programs; multi-year collaborations for chemistry and bio-analytical support.
Expertise Areas
- Lipid nanoparticle formulation and optimization
- AI-driven modeling for nanoparticle design
- mRNA delivery and gene-editing delivery strategies
- Nanotechnology formulation and LNP characterization
Key Technologies
- Lipid nanoparticles (LNPs)
- AI / machine learning for nanoparticle modeling
- Digital molecular libraries
- Prodrug chemistry
News & Updates
Closed an initial seed financing round to support development of proprietary lipid technologies for RNA-LNP therapeutics; funding will advance lipid technology with reported in vivo potency and reduced toxicity in partner studies.
Interview published in BioTechniques discussing mRNA-LNP approaches and delivery challenges presented at ELRIG Research & Innovation 2025.
Company representative presented and participated in a panel discussing academic-industry collaboration and drug development challenges.
Keynote presentation on mRNA-LNP systems for new biologics at an RNA institute symposium; ongoing advisory relationship with the institute.
Whitepaper describing an AI model for predicting LNP performance across heterogeneous datasets and benchmarking against existing approaches.
Completed acquisition and integration of a molecular library of lipid delivery compounds to accelerate LNP design and product candidate discovery; intellectual property filings associated with the assets.
Closed an initial seed financing round to support development of proprietary lipid technologies for RNA-LNP therapeutics; funding will advance lipid technology with reported in vivo potency and reduced toxicity in partner studies.
Interview published in BioTechniques discussing mRNA-LNP approaches and delivery challenges presented at ELRIG Research & Innovation 2025.
Company representative presented and participated in a panel discussing academic-industry collaboration and drug development challenges.
Keynote presentation on mRNA-LNP systems for new biologics at an RNA institute symposium; ongoing advisory relationship with the institute.
Whitepaper describing an AI model for predicting LNP performance across heterogeneous datasets and benchmarking against existing approaches.
Completed acquisition and integration of a molecular library of lipid delivery compounds to accelerate LNP design and product candidate discovery; intellectual property filings associated with the assets.